72 related articles for article (PubMed ID: 11394884)
1. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.
Wada M; Wada NA; Shirono H; Taniguchi K; Tsuchie H; Koga J
Biochem Biophys Res Commun; 2001 Jun; 284(2):346-51. PubMed ID: 11394884
[TBL] [Abstract][Full Text] [Related]
2. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.
Alfano M; Sidenius N; Blasi F; Poli G
J Leukoc Biol; 2003 Nov; 74(5):750-6. PubMed ID: 12960238
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion.
Elia C; Cassol E; Sidenius N; Blasi F; Castagna A; Poli G; Alfano M
J Leukoc Biol; 2007 Nov; 82(5):1212-20. PubMed ID: 17704294
[TBL] [Abstract][Full Text] [Related]
4. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
5. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
6. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
7. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
[TBL] [Abstract][Full Text] [Related]
8. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
9. Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV-1.
Keppler OT; Tibroni N; Venzke S; Rauch S; Fackler OT
J Leukoc Biol; 2006 Mar; 79(3):616-27. PubMed ID: 16365153
[TBL] [Abstract][Full Text] [Related]
10. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
11. A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation.
Chang TL; Mosoian A; Pine R; Klotman ME; Moore JP
J Virol; 2002 Jan; 76(2):569-81. PubMed ID: 11752148
[TBL] [Abstract][Full Text] [Related]
12. Derivation of infectious HIV-1 molecular clones with LTR mutations: sensitivity to the CD8+ cell noncytotoxic anti-HIV response.
Bonneau KR; Ng S; Foster H; Choi KB; Berkhout B; Rabson A; Mackewicz CE; Levy JA
Virology; 2008 Mar; 373(1):30-8. PubMed ID: 18086484
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
Tewari D; Notkins AL; Zhou P
J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.
Zhao G; Yuan C; Bian C; Hou X; Shi X; Ye X; Huang Z; Huang M
Protein Expr Purif; 2006 Sep; 49(1):71-7. PubMed ID: 16806969
[TBL] [Abstract][Full Text] [Related]
16. Influenza virus activates human immunodeficiency virus type-1 gene expression in human CD4-expressing T cells through an NF-kappaB-dependent pathway.
Sun J; Bergeron M; Barbeau B; Boivin G; Tremblay MJ
Clin Immunol; 2005 Feb; 114(2):190-8. PubMed ID: 15639653
[TBL] [Abstract][Full Text] [Related]
17. Anti-viral activity of human antithrombin III.
Elmaleh DR; Brown NV; Geiben-Lynn R
Int J Mol Med; 2005 Aug; 16(2):191-200. PubMed ID: 16012749
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Ueshima S; Fukao H; Okada K; Matsuo O
Thromb Res; 2004; 113(1):41-9. PubMed ID: 15081564
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
20. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses.
Ramduth D; Chetty P; Mngquandaniso NC; Nene N; Harlow JD; Honeyborne I; Ntumba N; Gappoo S; Henry C; Jeena P; Addo MM; Altfeld M; Brander C; Day C; Coovadia H; Kiepiela P; Goulder P; Walker B
J Infect Dis; 2005 Nov; 192(9):1588-96. PubMed ID: 16206073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
